Given the association of ARID1A alteration with EBV and MSI, and responses to ICB in gastric cancer (11), we further investigated ARID1A. All three tumors with ARID1A mutations were TP53+GS− subtype and one patient showed PR while the other two patients showed PD. This evidence concerns the gene TP53 and gastric cancer.